Navigation Links
St. Jude Defines Eye Cancer Gene's Role in Retinal Development
Date:1/16/2008

Study provides the foundation for improving understanding of N-myc gene's role in the eyes' growth during fetal development when retinoblastoma forms

MEMPHIS, Tenn., Jan. 16 /PRNewswire-USNewswire/ -- A genetic discovery led by scientists at St. Jude Children's Research Hospital helps answer a long-standing mystery about the eyes of vertebrates, and may translate into a deeper understanding of how genes coordinate the complex process of eye formation and how a rare pediatric eye cancer progresses.

"A series of complex developmental processes must be carefully orchestrated for the eye to form correctly," said Michael Dyer, Ph.D., associate member in the St. Jude Department of Developmental Neurobiology. "One important aspect of this coordination is that retinal thickness be the same, irrespective of eye size. For example, the mouse eye is about 5,000 times smaller than that of the elephant eye, but the retinal thickness in these two species is comparable."

Working with mice, the researchers found that a gene called N-myc coordinates the growth of the retina and other eye structures to ensure the retina has the proper thickness necessary to convert light from the lens into nerve impulses that the brain transforms into images. Until their study, reported in the Jan. 15 issue of "Genes & Development," almost nothing was known about the molecular mechanisms responsible for properly sizing the retina. Dyer is the paper's senior author.

"This represents the first example of a role for a Myc gene in retinal development," Dyer said. "On the basis of our data, we propose that N-myc plays a central role in coordinating retinal proliferation with eye growth during development."

Genes in the Myc family carry out vital roles during prenatal development by regulating the proliferation, size, differentiation and survival of cells. Myc genes are also proto-oncogenes--genes in which a mutation enables them to transform normal cells
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anesiva Defines Regulatory Pathway for Adlea with FDA
2. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
5. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
6. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
7. Marital Status Doesnt Affect Lung Cancer Survival
8. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
9. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
10. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
11. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3New Research Shows a Vitamin/Nutriceutical Formulation Improves Memory and Cognitive Performance in Community-Dwelling Adults 2Van Andel Institute Cuts Ribbon on $178 Million Expansion 2Van Andel Institute Cuts Ribbon on $178 Million Expansion 3Van Andel Institute Cuts Ribbon on $178 Million Expansion 4KGI Establishes Post Baccalaureate Premedical Program 58514 1KGI Establishes Post Baccalaureate Premedical Program 58514 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 1Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 3MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 1MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 2MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 3MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 4MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 5
Breaking Medicine News(10 mins):Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 3Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 2Health News:The Flag Company, Inc.'s Recently Released “Feel Good” Light Lenses Grows Into Its Own Website 3Health News:Senator Ben Nelson Puts U.S. Bishops' Interests Ahead of Americans' Healthcare Needs 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3Health News:VitaminSpice Signs Agreement With Former CEO of Wal-Mart Stores Division for US Distribution 2